|
Phytochemicals | Species/studied material | Experimental model | Dose | Therapeutic uses | Mechanisms | Induced Neurotrophins | References |
|
Epigallocatechin-3-gallate | C57BL/6 mice | Sevoflurane-induced neurotoxicity | 25, 50, or 75 mg/kg | Neuroprotection | Activates CREB/BDNF/TrkB and PI3K/Akt/mTOR signalling pathway | BDNF | [110] |
Rats | Acrylamide-induced neurotoxicity | 10 mg/kg | Neuroprotection | Enhances acetylcholinesterase activity and reduces the expression of iNOS and COX-2 level | BDNF | [111] |
Sprague–Dawley rats | Spinal cord injury | 10 and 20 mg/kg | Neuroprotection | Upregulation of BDNF and GDNF | BDNF, GDNF | [112] |
PC12 cells | Oxidative-radical-stress-induced apoptosis | 0, 50, 100, 150 or, 200 μM | Neurodegenerative disorders | Activates PI3K/Akt and inhibits GSK-3 | NGF | [113] |
Curcumin | Rats | Stress-induced damage to hippocampal neurons | 5, 10, and 20 mg/kg | Enhances hippocampal neurogenesis | Upregulation of 5-HT(1A) receptors and BDNF | BDNF | [80]. |
Male Sprague–Dawley (SD) rats | 6-OHDA-induced Parkinson’s disease | 5, 10, and 20 mg/kg | Neural regeneration and neuroprotection | Activates Trk/PI3K signaling pathways | BDNF | [71] |
C57BL mice | MPTP-induced mice | 0.5% or 2.0% (w/w) | Neuroprotective effect | Increases expression of GDNF and TGFβ1 | GDNF | [114] |
Rats | Aβ-induced cognitive impairments | 50 and 2.5 mg/kg | Improves cognitive deficit and neuroprotection | Activates PI3K/Akt signaling pathways and inhibits GSK-3 | BDNF | [115] |
Adult and aged mice | D-galactose-induced | 300 mg/kg | Improves cognitive impairment | Activates CREB signaling in the hippocampal dentate gyrus | BDNF | [116] |
Rodent cortical neurons | | 5 and 10 μM | Neuroprotection | Mediates through BDNF/TrkB-MAPK/PI-3 K-CREB signaling pathway | BDNF | [63] |
Resveratrol | Adult Wistar rats | Two-vessel occlusion | 20 mg/kg | Neuritogenesis, neuroinflammation, and neuroprotection | Activates ERK-mediated CREB regulation, induces BDNF, NGF, and GDNF secretion, and inhibits IL10, IL-1β, and NF-κB levels | BDNF and NGF | [117] |
Female Wistar rats | Dopaminergic neurons | 25–100 μM | Produces neurotrophic effects | Promotes the release of neurotrophic factors | BDNF and GDNF | [118] |
Female Wistar rats | Astroglia-enriched cultures | 25-100 μmmol/L | Neurological diseases | Induces the phosphorylation of (ERK1/2) andCREB in astroglia | BDNF and GDNF | [119]. |
Male Wistar rats | Chronic unpredictable mild stress-induced behavioral abnormalities | 20, 40 and 80 mg/kg | Antidepressant-like effects | Upregulates pERK, pCREB, and BDNF levels in the hippocampus and amygdala | BDNF | [120] |
Male Wistar rats | Phenylephrine-induced contraction of vascular smooth muscle cells | 10 mg/kg | Neuroprotection | Increases BDNF serum concentrations and reduces the contractility of resistance arteries via NOS-3-independent mechanisms | BDNF | [121] |
Quercetin | Male Chinese Kunming mice | High-fat diet | 8.5 and 17 mg/kg | Improves cognitive impairment | Modulates PI3K/AKT/Nrf2 pathway and activates CREB pathway | BDNF | [122] |
Adult male Sprague Dawley rat | Hypobaric hypoxia-induced memory deficit | 50, 75 or 100 mg/kg | Ameliorates cognitive impairment | Regulates the expression of sirtuin 1, PGC-1α, and the proteins related with mitochondrial biogenesis and dynamics | BDNF | [123]. |
Male Wistar albino rats | Streptozotocin-induced diabetes model | 50 mg/kg | Neuroprotection | Akt survival pathway, enhances the level of TrkB and Bcl-2, and reduces the level of both cytochrome c and caspase-3 | BDNF and NGF | [124] |
Adult male albino rats | Polychlorinated biphenyls-induced neurotoxicity | 50 mg/kg | Protects and prevents neuronal damage | Prevents transmembrane tight junctional proteins and cytoplasmic accessory tight junctional proteins in the hippocampus and keeps the level of estradiol | BDNF | [125] |
Daidzein | H19-7/IGF-IR neural cell line | | 20 nM -2000 nM | Neuroprotection | Blocks a selective Trk receptors inhibitor, K252a | BDNF | [126] |
Alpinetin, luteolin, calycosin, isohamnerin | Primary rat astrocytes | | 10 μM | Improves neurodegenerative diseases | Triggers estrogen signaling | BDNF, GDNF and NGF | [85] |
Ginkgolide B | Cultured hippocampal neurons | Aβ25–35-induced apoptosis | 40 μg/ml | Neuroprotection | Upregulates BDNF | BDNF | [127] |
Naringin | Sprague-Dawley rats | Spinal cord injury | 20 and 40 mg/kg | Neuroprotection | Upregulates BDNF and VEGF and the inhibits the neural apoptosis | BDNF and VEGF | [128] |
Genistein | Primary rat astrocytes | | 10 μM | Improves neurodegenerative diseases | Triggers estrogen signaling | BDNF, GDNF and NGF | [85] |
H19-7/IGF-IR neural cell line | | 20 nM -2000 nM | Neuroprotection | Blocks a selective Trk receptors inhibitor, K252a | BDNF | [126] |
Butein, fisetin | Mice | Glutamate-induced neurotoxicity | 40 mg/kg | Enhances cognitive effects | Inhibits iNOS and COX-2 and reactivates CREB-BDNF pathway | BDNF | [129] |
Apigenin | Mice | MPTP-induced Parkinson’s disease mice | 5, 10 and 20 mg/kg | Treatment of Parkinson’s disease | Reduces oxidative damage, neuroinflammation, and microglial activation | BDNF | [130] |
Epicatechin | Male C57BL/6 J mice | Hippocampus of anxiety mice | 4 mg/day | Treatment of mood disorders | Modulates monoaminergic and neurotrophic systems | BDNF | [131] |
Rosmarinic acid | Sprague-Dawley rats | Chronic unpredictable stress | 10 mg/kg | Improves depressive-like behaviors | Alters in ERK1/2 signaling | BDNF | [132] |
Baicalein | Mice | Chronic unpredictable mild stress | 1, 2, and 4 mg/kg | Treatment of depression | Triggers ERK-mediated neurotrophic action | BDNF | [133]. |
Ferulic acid | Mice | Corticosterone-induced | 50, 100, or 250 mg/kg | Treatment of mood disorders | Increases CREB phosphorylation and BDNF mRNA level in the hippocampus | BDNF | [134]. |
|